The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
As the United States accelerates the search for a coronavirus vaccine, tensions have erupted between government scientists and Moderna Inc., one of the leading developers, Reuters has learned.
Regeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
Emergent BioSolutions entered a five-year manufacturing services deal with Janssen Pharmaceutical to manufacture Johnson & Johnson’s Ad26.COV2-S COVID-19 vaccine.
COVID-19 vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said.
U.S. National Institutes of Health Director Dr. Francis Collins said he was optimistic that the Trump administration’s vaccine-acceleration program “Operation Warp Speed” will generate a safe and effective vaccine for COVID-19 by year end.
In the battle against COVID-19, the United States continues to see spikes in multiple states, and the nation’s top virus expert says the next few weeks will be critical to contain the spread of the disease that has caused the death of more than 121,000 Americans.
Eli Lilly will assess the company’s JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
In order to generate more shots on goal in the development of a vaccine for COVID-19, the U.S. government will provide funds for the development of three vaccine programs against the disease.
Polls show that up to 50 percent of Americans are unwilling to be vaccinated against COVID-19 once a vaccine becomes available.